Loading
Uromigos-Kidney Cancer

The Uromigos

The Uromigos | August 9, 2022

Bernard Escudier, MD, joins The Uromigos to talk about his career development and work in the field of kidney cancer.

The Uromigos

The Uromigos | July 11, 2022

Kimryn Rathmell, MD, PhD, discusses highlights from the kidney cancer guidelines presented at the ASCO Annual Meeting.

The Uromigos

The Uromigos | June 27, 2022

Darren Feldman describes different approaches to relapsed germ cell tumors and the TIGER study.

The Uromigos

The Uromigos | May 2, 2022

David Braun gives an overview of the mechanisms of response to PD1 therapy in renal cancer.

The Uromigos

The Uromigos | April 22, 2022

Michael Staehler gives an overview of the abstracts presented in the oral session from EIKCS 2022.

The Uromigos

The Uromigos | March 21, 2022

Dr. David McDermott attempts to get his point across he discusses favorable risk clear cell renal cancer and its treatments.

The Uromigos

The Uromigos | February 17, 2022

Dr. Laurence Albiges gives an overview of the new ESMO RCC guidelines, and Brian challenges her and Tom.

The Uromigos

The Uromigos | January 24, 2022

Dr. David Cella unpacks the data across these studies and makes some conclusions.

GU Oncology Now Editors

The Uromigos | December 28, 2021

Dr. David McDermott describes his clinical cancer research paper on treatment-free survival in kidney cancer.

The Uromigos

The Uromigos | December 21, 2021

Chad Tang discusses his oncology paper recently published in Lancet.

The Uromigos

The Uromigos | December 17, 2021

Tom and Brian take a look back at the year in kidney cancer with Dr. Toni Choueiri.

The Uromigos

The Uromigos | October 29, 2021

Dr. Mike Atkins discusses the role of CTLA4 inhibition in RCC.

The Uromigos Episode 117: PD1/VEGF Adverse Event Management in Renal Cancer
GU Oncology Now Editors

The Uromigos | October 11, 2021

Betsy Plimack discusses the tricks of the trade for adverse event management.

GU Oncology Now Editors

The Uromigos | September 19, 2021

Dr. Janet Brown discusses intermittent VEGF TKI therapy in the context of the STAR clinical trial.

The Uromigos

The Uromigos | September 19, 2021

Dr. Naveed Vasudev discusses IPI dosing and findings from the PRISM study.

The Uromigos

The Uromigos | August 16, 2021

Dr. Nick Vogelzang discusses his career and describes treatment advances in renal cell carcinoma.

The Uromigos

The Uromigos | July 14, 2021

Dr. Grant Stewart discusses renal cancer data presented at the 2021 EAU Conference.

The Uromigos

The Uromigos | June 8, 2021

Dr. Nizar Tannir and the Uromigos discuss the phase 3 trial of cabozantinib +/- a glutaminase inhibitor in refractory mRCC.

The Uromigos

The Uromigos | June 7, 2021

The Uromigos discuss a plenary presentation on adjuvant pembrolizumab versus placebo in high-risk resected RCC.

The Uromigos

The Uromigos | June 6, 2021

The Uromigos and Monty Pal discuss data on microbiome modification's impact on immune-oncology clinical efficacy in mRCC.